Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,039.11
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Regeneron's Dupixent COPD Sales To Reach $20B By 2026, Analyst Sees Larger Addressable Market
June 13, 2024
Analyst projects Regeneron's Dupixent to drive COPD sales surge, envisioning $20B market by 2026 on larger addressable market.
Via
Benzinga
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
June 13, 2024
The companies are closing in on the finish line for two new COPD treatments.
Via
Investor's Business Daily
Why Big-Name Biotech Regeneron Pharma Just Joined The 1,000-Club
June 12, 2024
Enthusiasm is growing for a looming approval in COPD treatment.
Via
Investor's Business Daily
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
June 11, 2024
Via
Benzinga
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
June 07, 2024
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.
Via
Benzinga
Stock Split Watch: 3 Growth Stocks That Could Be Next
June 07, 2024
Success has some downsides, including a much higher stock price.
Via
The Motley Fool
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
June 04, 2024
Via
Benzinga
Navigating 14 Analyst Ratings For Regeneron Pharmaceuticals
June 04, 2024
Via
Benzinga
2 Biotech Stocks to Buy in May
May 25, 2024
You could buy these in any month, really.
Via
The Motley Fool
What's Going On With FibroGen Stock Tuesday?
June 04, 2024
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial...
Via
Benzinga
Exposures
Product Safety
FibroGen Stock Is Surging After The Bell: What's Going On?
June 03, 2024
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial...
Via
Benzinga
Exposures
Product Safety
Here's How Much $100 Invested In Regeneron Pharmaceuticals 10 Years Ago Would Be Worth Today
June 03, 2024
Via
Benzinga
FDA Extends Review Deadline For Regeneron/Sanofi's Dupixent For 'Smoker's Lungs' Disease
May 31, 2024
The FDA extends the target action date for reviewing Dupixent as an add-on treatment for uncontrolled COPD to September 27, 2024. This follows the submission of additional efficacy analyses from...
Via
Benzinga
Exposures
Product Safety
What's Going On With Biohaven Stock Wednesday?
May 29, 2024
The company announced it dosed a patient with a new possible treatment for certain cancers, showcased positive data from two different studies and presented other updates.
Via
Benzinga
(REGN) - Analyzing Regeneron Pharmaceuticals's Short Interest
May 20, 2024
Via
Benzinga
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
May 17, 2024
Via
Benzinga
Assessing Regeneron Pharmaceuticals: Insights From 16 Financial Analysts
May 03, 2024
Via
Benzinga
After UnitedHealth Cyberattack, Drug Distributor Cencora Notifies Americans' Health Information Stolen In Data Breach In February
May 24, 2024
Cencora reports a cyberattack exposing sensitive medical information, including patient names, addresses, birth dates, diagnoses, and medications.
Via
Benzinga
Topics
Data Breach
Exposures
Information Security
3 Stocks That Have Turned $25,000 Into More Than $1 Million in 15 Years
May 23, 2024
It might not be too late to invest in these impressive growth stocks.
Via
The Motley Fool
Large Cap Biopharmaceuticals Performance
May 20, 2024
The biotech sector remains a laggard YTD as can be seen by the IBB.
Via
Talk Markets
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
May 20, 2024
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.
Via
InvestorPlace
These 2 No-Brainer Growth Stocks Are Breaking New Ground
May 16, 2024
The future keeps getting brighter for these companies.
Via
The Motley Fool
Here's How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 10 Years
May 14, 2024
Via
Benzinga
Week Of May 13, 2024: What's In Store For The Markets
May 13, 2024
Timeless Wisdom and timely ideas including general market commentary along with stocks to watch.
Via
Talk Markets
Healthcare And Biotech Investing 101: What You Need To Know.
May 13, 2024
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Sell In May? No Way!
May 11, 2024
Many investors and members of the financial media have been asking if it would be prudent to heed the old Wall Street adage to “sell in May and go away.
Via
Talk Markets
3 Biotech Stocks With the Potential to Make You an Overnight Millionaire
May 04, 2024
Don’t miss out on these stocks that could rock your portfolio with massive growth following FDA approvals and breakthrough treatments.
Via
InvestorPlace
Exposures
Product Safety
Stock Market Rallies On Fed, Jobs Report, Apple: Weekly Review
May 03, 2024
The Nasdaq regained its 50-day line Friday. The other indexes hit resistance.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Shhh! 3 Secret Pharma Stocks Flying Below Wall Street’s Radar
May 03, 2024
Discover three under-the-radar pharma stocks poised for significant growth in 2024. Explore their product pipelines and potential gains.
Via
InvestorPlace
Regeneron Pharmaceuticals Targets Quality Weight Loss In Latest Obesity Innovation
May 02, 2024
Regeneron Pharmaceuticals Q1 2024 earnings: EPS down 5%, sales miss; Eylea US sales drop 16%, Dupixent offsets. Oncology treatment Libtayo sales surge 49%.
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
31
32
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.